Researchers at Roswell Park Cancer Institute (RPCI) have uncovered new information that may begin to explain why many African American women are more likely to be diagnosed with aggressive, often deadly forms of breast cancer. Their findings also strengthen evidence that increased dietary folate...
Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations that are closely tied to breast and ovarian cancers, according to researchers at New York University (NYU) Langone Medical Center. Senior investigator Agnel Sfeir,...
A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never-before- seen flood of mutations in their disease in very short periods of time. The findings were published by Shlien et al in Nature...
Scientists at St. Jude Children's Research Hospital have discovered about 10% of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood ...
In a study reported in The New England Journal of Medicine, Jaiswal et al found somatic mutations associated with hematologic cancers at increasing frequency with increasing age, with presence of the mutations being associated with increased risk of hematologic cancers, all-cause mortality,...
In a study reported in The New England Journal of Medicine, Genovese et al found that clonal hematopoiesis with somatic mutations is increasingly common with greater age and is associated with increased risk of hematologic cancer. The presence of such clonal hematopoiesis in apparently healthy...
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
Approximately 5% to 6% of cases of colorectal cancer are associated with germline mutations conferring an inherited predisposition for disease. As reported by Stoffel et al in the Journal of Clinical Oncology, ASCO has endorsed, with qualifying statements, the European Society for Medical Oncology...
After initiating several biophysical computational studies, researchers have identified mutations that destabilize a DNA structure that turns a gene “off.” They found that these mutations occur at four specific sites in the human telomerase reverse transcriptase (hTERT) promoter in over ...
TH-302 is a hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. In a phase II trial reported in the Journal of Clinical Oncology, Borad et al found that the addition of TH-302 to gemcitabine improved progression-free survival in patients...
Today’s approval by the U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian...
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three ...
Next-generation sequencing in malignant pleural mesothelioma tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival, and cell proliferation pathways, according to a study by Lo Iacono et al in the Journal of Thoracic...
In a study to identify causative mutations in patients with Gorlin syndrome without PTCH1 mutations, Smith et al found that germline mutations in SUFU were associated with Gorlin syndrome and with increased likelihood of Gorlin syndrome–associated childhood medulloblastoma. The study is...
In a phase I study, a DNA vaccine targeting the breast cancer–associated antigen mammaglobin-A (MAM-A) was found to be safe and effective in eliciting immune responses in women with metastatic breast cancer. Preliminary evidence also suggests that the vaccine improved progression-free...
In a phase Ib/II study of patients with relapsed or refractory acute myeloid leukemia (AML), the addition of vosaroxin to cytarabine demonstrated antileukemic activity and an acceptable risk-benefit profile, according to a study by Lancet et al in Haematologica. Based on the findings from this...
Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...
The combination of different patterns of sun exposure experienced by children and biomarkers of melanoma risk, such as the number of freckles or moles that develop as a result, may play a large role in future melanoma risk, a study investigating gene and environmental interactions has found....
In a phase III trial reported in the Journal of Clinical Oncology, O’Shaughnessy et al found that the addition of iniparib to gemcitabine and carboplatin did not improve overall survival or progression-free survival in patients with metastatic triple-negative breast cancer. An exploratory...
Olaparib, an experimental twice-daily oral cancer drug, produced an overall tumor response rate of 26% in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to a phase II study reported by Kaufman et al in the Journal of Clinical Oncology. The positive response provides...
In a prospective Chinese study reported in the Journal of Clinical Oncology, Seto et al found a 2-year rate of hepatitis B virus (HBV) reactivation of 41.5% in hepatitis B surface antigen (HBsAg)-negative and anti–hepatitis B core antigen antibody (anti-HBc)–positive patients receiving...
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between kidney cancer and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published by Scelo et al in Nature Communications, have important...
In a study reported in The New England Journal of Medicine, Maude et al reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells. Study Details In the...
ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association of Molecular Pathologists (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor ...
A study involving a patient with metastatic anaplastic thyroid cancer who achieved a near-complete response to everolimus (Afinitor) that lasted for 18 months, followed by progressive disease, has revealed a previously unknown mutation in the TSC2 gene and in the mTOR protein. The discovery...
In a study reported in the Journal of the National Cancer Institute, Prat et al found that there was little difference in downstream gene or protein expression according to intrinsic breast cancer subtypes among clinical HER2-positive vs -negative breast cancers and that clinical HER2 status did...
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...
Epidermal growth factor receptor (EGFR) mutations found in the circulating-free tumor DNA from the plasma of advanced non–small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA, according to new data reported by Douillard et...
An international scientific collaboration led by Baylor College of Medicine as part of The Cancer Genome Atlas initiative has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer. The study, which describes the landscape of somatic genomic alterations of...
In a study reported in a letter to The New England Journal of Medicine, Dreijerink et al in the International Breast Cancer in MEN1 Study Group identified a high risk of breast cancer in women with multiple endocrine neoplasia type 1 (MEN1). MEN1 is caused by germline mutations in the MEN1...
The Cancer Genome Atlas Research Network has recently reported its comprehensive molecular profiling of lung adenocarcinoma in Nature. Findings included a high rate of somatic mutations including alterations in tumor-suppressor genes, chromatin-modifying genes, and RNA-splicing genes and suggested...
The U.S. Food and Drug Administration (FDA) today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or...
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...
Cancer research lost a pioneer on August 3, 2014, with the passing of Emmanuel Farber, MD, PhD, a renowned pathologist who made fundamental contributions to our understanding of chemical carcinogenesis. Dr. Farber’s studies in experimental pathology demonstrated that chemical carcinogens are...
Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other...
In a study reported in the Journal of Clinical Oncology, Sabine et al found that PIK3CA mutation was not an independent predictor of distant relapse-free survival among postmenopausal women with estrogen receptor–positive breast cancer receiving endocrine therapy in the TEAM (Exemestane...
Investigators of The Cancer Genome Atlas project have developed a molecular classification that divides gastric cancer into four major genomic subtypes, according to a study published in Nature. They include (1) tumors positive for the Epstein-Barr virus (EBV) that display recurrent PIK3CA...
Noninvasive quantitative computed tomography–based texture analysis can accurately differentiate the presence of a KRAS mutation from pan–wild-type non–small cell lung cancer (NSCLC), based on the results of a study in PLOS ONE. Weiss et al reported that this tumor heterogeneity...
In a study reported in the Journal of the National Cancer Institute, Noreen et al found that aspirin and hormone-replacement therapy reduced age-related gene promoter DNA methylation, and smoking and high body mass index (BMI) increased methylation in the colonic mucosa in women. Similar...
Researchers from Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and other centers have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. Knowledge of these mutations could potentially identify a...
Although cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes represents an effective treatment for patients with metastatic melanoma, the antigen targets recognized by these effective tumor-infiltrating lymphocytes remain unclear. According to a new study, a novel...
The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract O-0022). “Around 50%...
New research published online in Blood suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. Potential Connections Previous studies have shown that the intensive treatment...
A unique public-private collaboration among the National Cancer Institute (NCI), SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global...
Around a quarter of smokers who carry a mutation in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists described a previously unknown link between lung cancer and a particular BRCA2 mutation, which occurs in around 2% of...
In a recent study by the Lung Cancer Mutation Consortium (LCMC), investigators incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64% of tumors from patients in this study. According to data from this study...
In a phase II feasibility study (MRC FOCUS3) reported in British Journal of Cancer, Maughan et al used KRAS and BRAF mutation status and topoisomerase-1 expression status to randomly assign patients with advanced colorectal cancer to molecular hypothesis–driven treatment or control treatment. ...